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Abstract Iron can play a role in colorectal cancer (CRC)
development. The expression of genes involved in iron
metabolism and its regulation in CRC has not been
investigated well. Also the correlation between the level of
iron-related genes expression and cancer progression is not
known. In this study we collected paired samples of pri-
mary adenocarcinoma and adjacent normal mucosa from
73 patients. We assessed the mRNA or miRNA levels of 21
genes and verify their association with clinicopathological
characteristics of CRC patients. Our experiments revealed,
that the level of divalent metal transporter 1 transcript is
well correlated with mRNA levels of iron regulatory pro-
teins (IRPs) in tumor specimens. We have shown, that
IRP2 can also be engaged in the mRNA stabilization of
other iron transporter–transferrin receptor 1 (TfR1) in early
stage of disease, however, in more advanced stages of
CRC, mRNA level of TfR1 is related to miR-31 level. For
the first time we have shown, that ferroportin concentration
is significantly associated with miR-194 level, causing the
reduction of this transporter amount in tumor tissues of
patients with more advanced stages of CRC. We have also
shown the alterations in expressing profile of miR-31, miR-
133a, miR-141, miR-145, miR-149, miR-182 and miR-
194, which were observed even in the early stage of dis-
ease, and identified a set of genes, which take place in
correct assigning of patients in dependence of CRC stage.
These iron-related genes could become potential diagnostic
or prognostic indicators for patients with CRC.
Keywords Colorectal adenocarcinoma  Iron
metabolism  MiRNA expressing profile  Diagnosis
of cancer
Introduction
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and the second in females
worldwide, and ranks fourth and third for cancer-related
mortality among males and females, respectively [1]. There
is a body of evidence for a role of iron in CRC develop-
ment. Epidemiological studies revealed the association of
elevated total body iron and a high dietary iron intake with
CRC risk [2, 3]. It was also confirmed with the observation,
that patients with HFE mutations, suffering from iron
overload condition (hereditary hemochromatosis), had an
increased risk of CRC [4]. Iron is widely involved in many
important metabolic processes, such as electron transport,
oxygen delivery, enzymes and/or coenzymes activity, and
also DNA synthesis, which is intensified in proliferating
cancer cells. On the other hand, many symptoms are
associated with CRC, and iron deficiency anaemia (IDA) is
a classical indicator of this malignancy. It is present in
11–57 % of cancers and is more common in patients with
right-sided tumors (65–80 % have IDA) [5–7]. Anaemia is
presumed to be a result of the chronic occult blood loss
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related to the presence of tumor in the right colon com-
pared to the rectal bleeding of left sided tumors, which is
detected sooner [8]. Thus, various perturbations of iron
metabolism can be observed in patients with colorectal
adenocarcinoma.
Iron is absorbed from the diet via the duodenal entero-
cytes. Free ferric iron is reduced to ferrous state by cyto-
chrome b-like ferrireductase (Dcytb), and then transferred
through the apical enterocyte membrane via divalent metal
transporter 1 (DMT1). Iron can be bound to intestinal fer-
ritin (Fn) and stored, or moved to the basolateral surface of
the cell and exported by ferroportin (FPN1). After reoxi-
dation to its ferric state by ferrooxidase hephaestin (Heph),
iron is bound to serum transferrin (Tf) for distribution to
tissues. On the surface of target cells, the diferric Tf is
recognized by two highly specific transferrin receptors
(TfRs), TfR1 and TfR2, which allow the cellular uptake of
transferrin-bound iron by the receptor-mediated endocyto-
sis. Acidification (pH 5.5) of the endosomes results in
protein conformation changes following iron dissociation
from Tf. Ferric iron is then reduced and transported from
the endosome to the cytoplasm by DMT1. The Tf cycle is
completed when the endosome fuses with the plasma
membrane, returning apo-Tf to the circulation and TfR1 to
the plasma membrane [9]. The target for transferrin-bound
iron can be the bone marrow, where erythrocyte formation,
heme synthesis and also iron utilization is performed, or
hepatocytes, where iron is bound to Fn and stored. Mono-
nuclear macrophages involved in the recycling of iron from
senescent erythrocytes also accumulate iron. In case of iron
depletion, iron release from the storage cells is mediated by
FPN1 [10] and regulated via hepcidin [11].
Hepcidin, a key regulator of iron metabolism, can pre-
vent cellular iron export by internalization and the lyso-
somal degradation of ferroportin. Thus, increased hepatic
hepcidin synthesis in response to iron overload results in
subsequent inhibition of iron release from duodenal en-
terocytes by limiting the ferroportin available on the cell
surface. Conversely, decreased hepcidin production under
iron limiting conditions enhances FPN1 expression and
increases intestinal iron absorption [12]. Expression of
hepcidin is homeostatically regulated by anaemia, hypoxia,
inflammation [13], and also by the function of the hemo-
chromatosis protein (HFE), hemojuvelin (HJV) and TfR2,
as indicated by their mutation that decreased hepcidin
expression [14–16]. The fact that HFE forms a protein
complex with TfR [17] has led to the attractive hypothesis,
that a soluble factor such as diferric Tf (which competes
with HFE for TfR binding) might modulate HFE activity
and regulate a potential pathway signaling to the hepcidin
(HAMP) promoter [18]. To date, direct evidence support-
ing this hypothesis is lacking. Other data suggest that cell-
associated HJV is required for normal expression of
hepcidin in hepatocytes, and that soluble HJV negatively
regulates hepcidin expression in hepatocytes [19].
Other regulatory system of iron metabolism is dependent
on the activity of iron regulatory proteins (IRPs), IRP1 and
IRP2, which control the posttranscriptional expression of
genes modulating cellular iron uptake, export and storage.
Under low iron conditions, both proteins bind to conserved,
hairpin-like iron regulatory elements (IREs) present in the
untranslated regions (UTRs) of target mRNAs. The IRE/IRP
interactions result in stabilization and protection of mRNA
from endonucleolytic degradation (when IRPs are bound to
30-UTR of TfR1 mRNA) or in specific inhibition of mRNA
translation into protein (when bound to 50-UTR of the H- and
L-Fn mRNAs). Thus, iron-depleted cells increase their
capacity of transferrin-bound iron uptake by TfR1 and
minimize its sequestration into Fn stores. In contrast, in body
iron excess condition IRPs are inactivated promoting TfR1
mRNA degradation and Fn mRNA translation, which results
in inhibition of further iron uptake and increased iron
acquisition [20]. The presence of IREs in other iron-related
mRNAs (DMT1 and FPN1) suggests that their expression
may be controlled by cellular iron content, but it has not been
well understood yet [21, 22].
In the last few years new epigenetic regulators of iron
metabolism have emerged. MicroRNAs, short noncoding
RNAs, can control protein expression at the post-transcrip-
tional level. The principal mechanism of miRNA regulation of
gene expression is through the formation of a miRNA-induced
silencing complex in the cytoplasm, which binds to 30-UTRs
of target transcripts, thereby leading to repression of protein
translation or destabilization of the mRNAs with a significant
implication in pathology, especially in cancers [23]. Deregu-
lation of miRNA expression levels and some genetic altera-
tions were demonstrated in various cancers, including
colorectal adenocarcinoma [24, 25]. Investigations in tissue
samples have identified altered expressions of miRNAs
associated with tumorigenesis and tumor progression. Over-
expression of some tumor-inducing or tumor-promoting
miRNAs was demonstrated and these miRNAs became the
candidate biomarkers for diagnostics or monitoring, offering
relevant insights into tumorigenic mechanisms.
Proteins involved in iron metabolism are typically syn-
thesized by hepatocytes. However, iron metabolism alters
greatly in tumor cells and the up-regulation of TfRs on the
cell surface and Fn are the most well known modifications
[26]. The functions of iron-related proteins in association
with colorectal adenocarcinoma have been poorly investi-
gated. It was reported that CRC is related to overexpression
of genes involved in iron import (Dcytb, DMT1, and TfR1)
and decreased expression of genes involved in iron export
(FPN1 and Heph), which can promote iron storage in this
tumor [27]. Recent studies have indicated, that hepcidin
mRNA is overexpressed in 34 % of tumor tissues and is
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associated with iron deficiencies [28]. Hence, at the col-
onocyte level increased hepcidin levels may locally support
iron accumulation promoting cancer progression. Hitherto,
the alterations in expression of remaining genes involved in
iron metabolism and its regulation in cancer tissues has not
been investigated yet. Also the correlation between the
level of iron-related genes expression and cancer progres-
sion in patients is not known.
The aim of this study was the verification of hypothesis:
(1) whether the expression of analyzed genes is significantly
different in tumor versus normal colon tissues from the same
resection specimen in colorectal adenocarcinoma patients,
(2) whether the alterations in genes expression appear in
early stage of disease, (3) whether there is a correlation
between expression of analyzed genes and cancer progres-
sion, (4) whether there is a correlation between the level of
mRNA and homologous miRNA, and (5) whether there is a
correlation between expression levels and single nucleotide
polymorphisms of HAMP gene encoding hepcidin. To reach
these goals we collected paired samples of primary cancer
and adjacent normal mucosa from 73 CRC patients under-
going surgery. The mRNA or miRNA level of 21 genes
(DMT1, Fn, FPN1, HAMP, Heph, HFE, HJV, IRP1, IRP2,
Tf, TfR1, TfR2, miR-19a, miR-31, miR-133a, miR-141, miR-
145, miR-149, miR-182, miR-194, miR-758) was assessed
by quantitative RT-PCR analysis, and concentration of
chosen proteins (Fn and FPN1) was estimated by ELISA. In
this study we identified a set of discriminating genes in tumor
and normal colon tissues and evaluated their association with
clinicopathological characteristics of CRC patients. Now we
are going to investigate whether this difference is also
observed in serum.
Materials and methods
Collection of tissue samples
Paired samples of primary CRC and adjacent normal mucosa
(5–10 cm away from the tumor) were collected during sur-
gery from 73 patients in accordance with protocols approved
by the committee on the Ethics of Research in Human
Experimentation at the Medical University of Lodz (Poland),
and informed consent was obtained in accordance with the
Declaration of Helsinki. Among patients were 38 men and 35
women. Their mean age was 63.1 years (SD 10.4 years,
range 44–81 years). Based on the grading system, the
numbers of patients with well (G1), moderately (G2), and
poorly differentiated (G3) cancer cells were 21, 39, and 11,
respectively, and in 2 cases the differentiation could not be
evaluated. According to pTNM staging system of the
American Joint Committee on Cancer (AJCC), the numbers
of patients in stage I, IIA, IIIA, IIIB, IIIC and IV were 26, 12,
9, 11, 9, and 4, respectively. In 2 cases the assessment of
invaded lymph nodes was not feasible. The patient’s gender,
age, tumor location, local invasion, differentiation and
hemoglobin levels were obtained from surgical and patho-
logical records. All samples were stored at -80 C.
RNA extraction
Isolation of total RNA from frozen tumor and non-tumor
tissues was performed with mirVanaTM miRNA Isolation
Kit (Ambion) according to manufacturer’s recommenda-
tions. RNA was eluted with 30 lL of nuclease free water.
The concentration of RNA was detected with Picodrop.
RNA quality was determined using 2100 Bioanalyzer
(Agilent Technologies).
Reverse transcriptase reactions
The stem-loop RT primers for miRNA were purchased
from Applied Biosystems. TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems) was used to syn-
thesize cDNA of miRNA, according to the guidelines
provided by the manufacturer. 10 ng of total RNA was
added to the reaction tube to make up a final volume of
15 lL reaction mix and incubated (30 min, 16 C and
30 min, 42 C) in Thermocycler (Biometra). The reverse
transcriptase was inactivated (5 min, 85 C). To obtain
cDNA from mRNA, 200 ng of the extracted RNA was
reversely transcribed in a final volume of 20 lL with Ac-
cuScript PfuUltra II RT-PCR Kit (Stratagene), according
to manufacturer’s instructions. Samples were incubated
(10 min, 25 C and 30 min, 42 C) and held at -20 C.
Real time PCR (QPCR): detection of mRNA level
with SYBR Green
Real-time PCR was performed on Stratagene Mx3005P
instrument (Stratagene). The primer sequences of target
genes and the reference gene ribosomal protein L13a
(RPL13A) are given in Table 1. PCR reaction was carried
out using Brilliant II SYBR Green QPCR Master Mix
(Stratagene). 10 ng of cDNA and 100 nM primers were
added to the reaction tube to make up a final volume of 25 lL
reaction mix. The following run protocol was used: dena-
turation program (95 C, 10 min) and amplification and
quantification programs repeated 40 times (95 C, 15 s and
57 C, 1 min). Melting curves were generated for each real-
time RT-PCR to verify the specificity of PCR reaction. All
samples were amplified simultaneously in triplicate in a
single run. Relative quantification of mRNA was determined
by comparative Ct method [29]. The mRNA level of tested
gene was presented as the amount normalized to RPL13A
Mol Biol Rep (2013) 40:5573–5585 5575
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value, and was calculated as 2DCt , while the relative
expression analysis of target gene was presented as the n-fold
change in gene expression normalized to the reference gene
and relative to the control, and was calculated as 2DDCt .
Real time PCR (QPCR): detection of miRNA level
with TaqMan probes
Real-time PCR was performed on Stratagene Mx3005P
instrument (Stratagene). Brilliant QPCR Master Mix
(Stratagene) and 1 ng of cDNA were used in each PCR
reaction. Primers for miRNA genes were purchased from
Applied Biosystems. The U6 small nuclear RNA served as
an endogenous control for miRNA amplification. The
reaction was performed at 95 C for 10 min, followed by
40 amplification cycles at 95 C for 15 s and 60 C for
1 min. All samples were amplified simultaneously in trip-
licate in a single run. Relative quantification of miRNA
was determined by comparative Ct method.
Tissue homogenates preparation
Tumor and nontumor tissues were rinsed in ice-cold PBS
(0.02 mol/L, pH 7.2) to remove excess blood thoroughly.
25 mg of tissue was homogenized with a TissueRuptor
(QIAGEN) in 1 mL of PBS (0.01 mol/L, pH 7.4) supple-
mented with protease inhibitor cocktail tablets (Roche).
The resulting suspension was subjected to two freeze–thaw
cycles to further break the cell membranes. After that, the
homogenates were centrifugated (5 min, 5,0009g) and the
total protein in supernates was quantified with Micro
BCATM Protein Assay Kit, according to manufacturer’s
recommendations (ThermoSCIENTIFIC). The supernates
were stored at -20 C.
ELISA
The concentration of Fn and FPN1 in tumor and nontumor
specimens was estimated with Human Fn (FE) ELISA Kit
(BMASSAY) and Enzyme-linked Immunosorbent Assay Kit
For FPN1 (USCNK Life Science Inc.), respectively, according
to manufacturer’s recommendations. Human Actin Beta
(ACTb) ELISA Kit (BMASSAY) was used as an amount
control. Samples were measured photometrically at 450 nm
with a microplate reader (Multiskan Ascent, Thermo Labsys-
tems). The relative amount of protein was normalized to the
control, and calculated as tumor/nontumor concentration ratio.
DNA extraction
Tumor and nontumor tissues were homogenized with
TissueRuptor (QIAGEN) in lysis buffer. After incubation
(15 min, 55 C) 10 lL of RNase was added to the samples
and incubated (1 h, 55 C). Subsequently the samples were
incubated with 10 lL of proteinase K (1 h, 55 C) and then
extraction was performed. 0.5 mL of phenol:chloroform
(1:1) mix was added and samples were centrifuged (3 min,
13,0009g). Supernatant was transferred to fresh tubes and
0.5 mL of chloroform:isoamyl alcohol (24:1) mix was
added. After centrifugation (3 min, 13,0009g) supernatant
was transferred to fresh tubes and 100 lL of 10 M ammo-
nium acetate and 1 mL of ethanol 96 % were added. Samples
were frozen (-80 C) and centrifuged (10 min, 13,0009g).
Pellets were washed with cold ethanol 96 %, samples were
Table 1 Primer sequences used in QPCR and PCR reactions
Gene Forward 50–30 Reverse 50–30 Product size (bp)
DMT1 TCCACCATGACAGGAACCTA TGGCAATAGAGCGAGTCA 105
Fn GGAGAGGGAACATGCTGAGA GCACACTCCATTGCATTCAG 126
FPN1 ACAGCAGTCTACGGGCTGGT CTGTACCACCAGCGAGGTCT 117
HAMP CACAACAGACGGGACAACTT CGCAGCAGAAAATGCAGATG 129
Heph TTAAGCCCTCTCACCGTCATCA GCCAGAACAACGAGCAGAAGG 170
HFE GATCATGAGAGTCGCCGTGT ATGTGATCCCACCCTTTCAG 107
HJV CTGCCTACATTGGCACAACT CCTTGATGGAGAAGGAGAGC 66
IRP1 TGCTTCCTCAGGTGATTGGCTACA TAGCTCGGTCAGCAATGGACAACT 171
IRP2 ACCAGAGGTGGTTGGATGTGAGTT ACTCCTACTTGCCTGAGGTGCTTT 102
Tf AGCAGAGACCACCGAAGACT AGACAAACCCTCCATCCAAG 80
TfR1 GGTTGCAAATGCTGAAAGC AAGGAAGGGAATCCAGGTGT 147
TfR2 GTGGACCGACACGCACTAC TAGACGTCAGGGTCCTCCAG 123
RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 126
HAMP-exon1 CGGTCCCAGACACCAGAGCAAGC CCCTGCTGCCCTGCTAAGGACC 192
HAMP-exons2-3 GCCATCCTCTGCACCCCCTTCTG GGAAGGGAGGGGACGGGGGCA 320
5576 Mol Biol Rep (2013) 40:5573–5585
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centrifuged (10 min, 13,0009g) and pellets were resus-
pended with 50 lL of LoTE buffer (3 mM Tris–HCl (pH
7.5), 0.2 mM EDTA) and frozen (-80 C).
DNA sequencing analysis
Amplification of three exons of HAMP gene was conducted
using primers listed in Table 1. Starter binding to com-
plementary DNA matrix sites was carried out at 58 C. The
PCR product sequences were established by automatic
DNA sequencing. The occurrence of single nucleotide
polymorphisms was analyzed with Chromas and CLU-
STALW Software.
Statistical analysis
All calculations were performed with the STATISTICA Stat-
Soft Version 10. Data were ln-transformed to obtain a normal
distribution. Paired Student’s t test was used to evaluate the
difference between paired samples (tumor and normal tissues)
and one-way ANOVA followed by Tukey’s test was used to
compare the differences among groups. Correlation between
the expression of miRNAs, mRNAs and protein concentration
was confirmed using the Pearson’s correlation coefficient
analyses. Discriminant analysis was used to find a combination
of genes which characterizes different clinicopathological
features in colorectal adenocarcinoma patients. Statistical sig-
nificance was assumed to be p \0.05.
Results
Expression of iron-related genes in CRC and normal
mucosa specimens
Previous studies reported, that some of iron-related genes are
overexpressed in colorectal adenocarcinoma [27, 28]. To
investigate the alterations in expression of genes involved in
iron metabolism or its regulation, we examined over 20
genes. Among them 12 encoded proteins (DMT1, Fn, FPN1,
HAMP, Heph, HFE, HJV, IRP1, IRP2, Tf, TfR1, TfR2) and
nine encoded miRNAs (miR-19a, miR-31, miR-133a, miR-
141, miR-145, miR-149, miR-182, miR-194, miR-758).
Sequences of these miRNA genes are homological to 30-
UTRs of several iron-related genes (Table 2), according to
the DIANA Database, and thus analyzed miRNAs are con-
sidered to play a role in regulation of iron metabolism.
QPCR assay revealed, that all analyzed mRNAs were
detectable in both tumor and normal tissues tested, and Fn
mRNA was highly expressed in adenocarcinoma as well as in
control specimens, but not significantly different in these
tissues (Table 3). Most of analyzed mRNAs, except Heph,
IRP1 and Tf, were expressed more frequently in tumor than
in normal tissues, but difference between both specimens
reached significance (p \ 0.05) only in 3 of 12 analyzed
mRNAs (FPN1, IRP1 and Tf). Among this three genes FPN1
was up-regulated in CRC (p = 0.039), and IRP1 and Tf were
down-regulated in comparison to adjacent normal tissue
(p = 0.046 and p = 0.017, respectively).
Contrary to mRNAs, almost all examined miRNA genes
were expressed at higher levels in tested materials. The dif-
ference between miRNA levels in both tumor and normal tis-
sues were highly significant (p\ 0.001) in most genes
encoding miRNAs, except miR-19a and miR-758, in which the
level of mRNA remained almost the same (Table 3). The
expression intensities of miR-31, miR-141, miR-182 and miR-
194 in tumor tissues were significantly enhanced, and miR-
133a, miR-145 and miR-149 were decreased in comparison to
those in adjacent normal tissues, according to RT-QPCR data.
Alterations in genes expression in various
clinicopathological stages of CRC patients
Different expression of analyzed genes, especially encoding
miRNAs, was observed in patients suffering from colorectal
adenocarcinoma. To estimate, whether these alterations appear
Table 2 Prediction of miRNA
targets
Underlined letters are the
homological sequence of
miRNAs to target genes. The
homology of both RNAs
concerns only 7-nucleotide
sequence and not the whole
sequence of miRNA as is
observed in siRNAs




miR-19a AGUCAAAACGUAUCUAAACGUGU DMT1 89–95 7mer-1A
miR-31 UCGAUACGGUCGUAGAACGGA TfR1 527–533 8mer
miR133a GUCGACCAACUUCCCCUGGUUU Fn (light
chain)
114–120 8mer
miR-141 GGUCGAAAUGGUCUGUCACAAU TfR1 1,462–1,468 7mer-m8
miR-145 UCCCUAAGGACCCUUUUGACCUG TfR1 1,027–1,033 7mer-1A
miR-149 CCCUCACUUCUCUGCCUCGGUCU DMT1 35–41 7mer-m8
miR-182 UCACACUCAAGAUGGUAACGGUUU TfR1 810–816 7mer-1A
miR-194 AGGUGUACCUCAACGACAAUGU TfR1 1,439–1,435 7mer-1A
AGGUGUACCUCAACGACAAUGU FPN1 21–27 7mer-m8
miR-758 CCAAUCACCUGGUCCAGUGUUU TfR1 1,323–1,329 7mer-m8
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either in early stage of disease or depend on the progression of
CRC, we compared the expression of analyzed genes in various
clinicopathological features of this disease, including histo-
logical grade, depth of invasion, nodal status, tumor location,
diagnosis, and also gender and age of patients.
According to QPCR data, the expression profiles of HJV,
IRP2, TfR2 and miR-149 genes were dependent on depth of
tumor invasion. HJV, IRP2 and TfR2 were up-regulated and
mir-149 gene was down-regulated in T3 stage of CRC in
comparison to T1 and T2 stages (Fig. 1). There was no statis-
tically significant difference in the expression of remained iron-
related genes among various T stages. Additionally, the Heph
demonstrated higher expression in sigmoid colon than in
cecum or rectum as was shown in Fig. 2, whereas the tumor
location remained without significant influence for the
expression of other tested genes. Moreover, we compared the
expression of iron-related genes in male and female popula-
tions and found, that the Tf was significantly (p = 0.009)
overexpressed in women. The data did not reveal any additional
alterations in mRNA or miRNA levels in dependence on cancer
cell differentiation, nodal invasion, diagnosis or patients age.
Alteration in ferroportin concentration in colorectal
adenocarcinoma
To analyze, whether the alterations in gene expression were
observed at the protein level, we estimated the
concentration of two proteins Fn and FPN1, which can be
regulated by IRPs and/or miRNAs levels. Both proteins
were detectable in tumor as well as in normal tissues tested.
The high concentration of Fn, reaching 300 ng/mL in some
cases, was observed in adenocarcinoma and adjacent nor-
mal tissues as well, but the difference in Fn level between
these paired specimens was not significant. Contrary to
this, the amount of FPN1 was significantly higher
(p = 0.023) in normal than in tumor tissues (Fig. 3).
Genes involved in CRC progression
To identify genes, which can play a role in progression of
colorectal adenocarcinoma or discrimination of CRC
patients in dependence on clinicopathological characteris-
tics, we conducted discriminant analysis of iron-related
gene expression. The forward stepwise mode constructed
discriminant functions including all genes under study, and
showed that DMT1, HAMP, TfR2, miR-31, miR-149, miR-
182, miR-194 were the most significant parameters
responsible for progression of colorectal adenocarcinoma,
assigning all cases correctly (p \ 0.0001). Fig. 4a shows
that the alterations in expression of chosen genes can dis-
tinguish patients with the wide spectrum of cancer stages.
Moreover, the stepwise forward discriminant functions
including nine variables can correctly discriminate
(p \ 0.0006) all colorectal adenocarcinoma cases. Forward
Table 3 mRNA or miRNA
level determined in tumor and
normal tissues by QPCR
reactions
Gene Control (normal tissue) Sample (tumor tissue) Statistical
significance
Mean SD Mean SD
DMT1 -7.131 0.81 -6.979 1.10 p = 0.389
Fn 0.079 1.01 0.211 0.94 p = 0.600
FPN1 -6.203 2.60 -5.482 2.09 p = 0.039
HAMP -8.082 1.30 -7.548 1.77 p = 0.082
Heph -4.195 2.16 -4.538 2.34 p = 0.158
HFE -6.254 1.97 -6.173 2.28 p = 0.640
HJV -7.562 2.90 -6.812 2.44 p = 0.166
IRP1 -7.028 2.15 -7.350 2.13 p = 0.046
IRP2 -7.340 1.39 -7.315 1.68 p = 0.979
Tf -7.632 1.49 -8.535 1.59 p = 0.017
TfR1 -7.516 1.18 -7.291 1.50 p = 0.397
TfR2 -8.719 2.77 -8.426 2.91 p = 0.182
miR-19a -2.590 1.09 -2.353 1.07 p = 0.140
miR-31 -6.435 1.05 -4.078 1.37 p \ 0.001
miR-133a 0.098 1.54 -2.106 2.14 p \ 0.001
miR-141 -2.000 1.66 -0.697 1.45 p \ 0.001
miR-145 3.226 1.44 1.398 2.36 p \ 0.001
miR-149 -4.732 1.48 -6.092 1.32 p \ 0.001
miR-182 -7.410 1.67 -6.123 1.73 p \ 0.001
miR-194 -1.623 1.65 -0.747 2.38 p = 0.041
miR-758 -7.152 0.58 -7.225 0.69 p = 0.876
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stepwise mode showed that DMT1, IRP1, IRP2, Tf, miR-
31, miR-133a, miR-145, miR-149, miR-194 were the most
significant parameters responsible for proper diagnosis.
This set of genes was differently expressed in adenocar-
cinoma tubulare, adenocarcinoma tubulare/mucinosum and
adenocarcinoma mucinosum (Fig. 4b).
Correlation between mRNAs expression levels
in colorectal adenocarcinoma
It was shown, that IRPs can control the posttranscriptional
expression of genes by stabilization and protection of TfR1
mRNA from endonucleolytic degradation or inhibition of the
H- and L-Fn mRNAs translation into protein in liver and
macrophages [20]. To investigate whether this regulation is
also observed in CRC, we estimated the levels of IRP1 and
IRP2 mRNA and correlated them with TfR1 and Fn mRNA
levels, and also with expression levels of two other genes
(DMT1 and FPN1) containing IREs in UTRs. Correlation
coefficients values of mRNA levels, which reached the sta-
tistical significance at various stages and different histopa-
thological grades of CRC were shown in Tables 4 and 5.
Strong positive correlation was observed between TfR1
and both IRP mRNA levels in well and moderately dif-
ferentiated cancer cells. IRP2 expression profile was also
significantly associated with relative expression of both
genes encoding TfR in patients with stage I of cancer and
additionally with TfR2 transcript level in more advanced
Fig. 1 Expression of a HJV,
b IRP2, c TfR2 and d miR-149
genes in T1, T2 and T3 stages of
colorectal adenocarcinoma.
Data presented as mean ± SE
for the relative expression of
analyzed genes calculated as
ln 2DDCt . Significance of
differences between T2 and T3
stages, estimated with one-way
ANOVA and post hoc Tukey’s
test for HJV, IRP2, TfR2 and
miR-149 genes was p = 0.049,
p = 0.041, p = 0.016 and
p = 0.028, respectively
Fig. 2 Expression of Heph gene in tumors localized in various parts
of colon. Data presented as mean ± SE for the relative expression of
analyzed gene calculated as ln 2DDCt . Significance of differences,
estimated with one-way ANOVA and post hoc Tukey’s test was
p = 0.040
Fig. 3 Concentration of ferroportin in tumor and normal tissue,
assessed by ELISA assay. Data presented as mean ± SE, and
significance of differences, estimated with Wilcoxon signed-rank test
was p = 0.023, n = 73
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Fig. 4 Discriminant analysis of patients a in various stages of CRC,
according to pTNM system or b with different diagnosis of cancer.
a In this model 7 variables were used (DMT1, HAMP, TfR2, miR-31,
miR-149, miR-182, miR-194); Wilks’ lambda was 0.006, p \ 0.0001,
n = 71; Stage I (circles), Stage IIA (diamonds), Stages IIIA ? IIIB
(squares), Stages IIIC ? IV (triangles). b In this model 9 variables
were used (DMT1, IRP1, IRP2, Tf, miR-31, miR-133a, miR-145,
miR-149, miR-194); Wilks’ lambda was 0.046, p \ 0.0006, n = 73;
Adenocarcinoma tubulare (circles), Adenocarcinoma tubulare/mucin-
osum (squares), Adenocarcinoma mucinosum (diamonds)
Table 5 Correlation between relative expression of mRNAs or mRNA vs. miRNA in patients with different stages of colorectal adenocarcinoma
mRNA vs. mRNA or
mRNA vs. miRNA

















IRP1 vs. DMT1 r = 0.67 p = 0.012 r = 0.74 p = 0.157 r = -0.17 p = 0.752 r = -0.31 p = 0.687
IRP1 vs. FPN1 r = 0.38 p = 0.221 r = 0.05 p = 0.939 r = -0.77 p = 0.002 r = -0.52 p = 0.023
IRP2 vs. DMT1 r = 0.36 p = 0.233 r = 0.87 p = 0.056 r = 0.71 p = 0.012 r = 0.63 p = 0.026
IRP2 vs. TfR1 r = 0.84 p \ 0.001 r = 0.75 p = 0.147 r = 0.66 p = 0.153 r = 0.48 p = 0.515
IRP2 vs. TfR2 r = 0.67 p = 0.012 r = 0.20 p = 0.743 r = 0.87 p = 0.023 r = 0.76 p = 0.043
HAMP vs. HFE r = 0.44 p = 0.136 r = -0.07 p = 0.916 r = 0.79 p = 0.018 r = 0.79 p = 0.042
HAMP vs. HJV r = 0.59 p = 0.032 r = 0.15 p = 0.813 r = 0.55 p = 0.259 r = 0.69 p = 0.306
HFE vs. HJV r = 0.60 p = 0.030 r = 0.74 p = 0.013 r = 0.86 p = 0.028 r = 0.71 p = 0.085
HFE vs. Tf r = 0.66 p = 0.015 r = 0.07 p = 0.913 r = 0.40 p = 0.433 r = -0.62 p = 0.380
HFE vs. TfR1 r = 0.68 p = 0.011 r = 0.74 p = 0.151 r = 0.75 p = 0.087 r = 0.55 p = 0.453
HFE vs. TfR2 r = 0.31 p = 0.306 r = 0.34 p = 0.577 r = 0.82 p = 0.044 r = 0.81 p = 0.189
FPN1 vs.miR-194 r = 0.29 p = 0.369 r = 0.34 p = 0.571 r = -0.89 p \ 0.001 r = -0.51 p = 0.034
TfR1 vs. miR-31 r = -0.33 p = 0.265 r = 0.56 p = 0.325 r = 0.86 p = 0.029 r = 0.51 p = 0.048
TfR1 vs. miR-145 r = -0.37 p = 0.219 r = -0.09 p = 0.884 r = -0.87 p = 0.025 r = -0.64 p = 0.041
Table 4 Correlation between
relative expression of mRNAs
or mRNA vs. miRNA in
patients with well and
moderately differentiated cancer
cells











IRP1 vs. DMT1 r = 0.73 p = 0.039 r = 0.24 p = 0.330
IRP1 vs. TfR1 r = 0.73 p = 0.038 r = 0.29 p = 0.024
IRP2 vs. DMT1 r = 0.67 p = 0.067 r = 0.53 p = 0.021
IRP2 vs. TfR1 r = 0.84 p = 0.009 r = 0.72 p \ 0.001
HAMP vs. FPN1 r = -0.08 p = 0.848 r = 0.51 p = 0.035
HAMP vs. HFE r = -0.22 p = 0.605 r = 0.52 p = 0.029
HAMP vs. HJV r = -0.20 p = 0.641 r = 0.56 p = 0.015
HFE vs. HJV r = 0.71 p = 0.050 r = 0.77 p \ 0.001
TfR1 vs. miR-145 r = -0.06 p = 0.884 r = -0.58 p = 0.011
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stages of this disease. Moreover, IRP1 expression level was
also positively correlated with DMT1 mRNA level in early
stage of disease as well as in first grade of cancer, however
in patients having lymph nodes invaded by the tumor IRP1
was negatively associated with relative expression of gene
encoding other transporter protein FPN1. In contrast, IRP2
mRNA level was positively correlated with DMT1 mRNA
level in more invasive stages of CRC and in moderately
differentiated tumor cells.
Iron regulatory mechanism is also modulated by hep-
cidin level, which expression is related to expression of
HFE or HJV genes in liver [14, 15]. To investigate, whe-
ther this mechanism is also observed locally in CRC we
correlated HAMP mRNA level with HFE and HJV mRNA
expression levels and also with FPN1, which is a receptor
for hepcidin. Association between HAMP and FPN1
mRNA levels was found in moderately differentiated
cancer cells. Also positive correlation between HAMP and
HFE mRNA levels was observed in more advanced stages
and grades of this disease. Contrary, association between
relative expression of genes encoding hepcidin or its sec-
ond regulatory protein hemojuvelin was shown to be sig-
nificant in early stage of CRC, as well as in grade 2 of
cancer. Moreover, association between both hepcidin reg-
ulatory genes (HFE and HJV) was found in all grades and
stages of this disease, except stages IIIB and IV of cancer.
Additionally, HFE mRNA level was positively correlated
with Tf as well as with TfR1 mRNA in stage I of CRC and
also with TfR2 in more advanced stages of this disease.
Correlation between mRNA expression
and homologous miRNA levels in CRC
Other regulatory mechanism of iron metabolism is depen-
ded on presence or absence of miRNAs in the tissue. All
analyzed miRNAs, according to DIANA Database, are
homological to 30-UTRs of several iron-related genes
(Table 2). We analyzed the correlation between miRNAs
and the expression of target genes levels in various grades
of CRC and in different stages of this disease, and the
correlation coefficients values, which reached the statistical
significance were listed in Tables 4 and 5.
TfR1 expression level was positively correlated with
miR-31 and inversely associated with miR-145 levels in
more advanced stages of colorectal adenocarcinoma pre-
senting higher nodal status. TfR1 expression level was also
negatively correlated with miR-145 level in moderately
differentiated but not with well differentiated cancer cells.
Strong inverse correlation was also observed between
levels of FPN1 mRNA and miR-194 in patients having
lymph nodes invaded by the tumor. Remained miRNAs,
which were analyzed in this study were not associated with
their target genes in any stage and grade of CRC.
Correlation between mRNA or miRNA expression
and protein level in tumor tissue
To further investigate, whether those correlations can be
confirmed at the protein level, we estimated the concen-
tration of ferritin and ferroportin in tumor and normal
specimens. Strong negative correlation (r = -0.66,
p = 0.002) in IIIA and IIIB stages of CRC was observed
between FPN1 and miR-194 levels (Fig. 5), but not with
FPN1 and IRP1 mRNA levels. However, concentration of
this transporter was not associated with its regulatory
molecules in early stages of this disease. Similarly to
FPN1, the level of other analyzed protein Fn was nega-
tively associated with IRP1 mRNA level but positively
correlated with miR-133a level (r = -0.97, p \ 0.001 and
r = 0.56, p = 0.011, respectively) in patients having
lymph nodes invaded by the tumor, which was shown in
Fig. 6.
Fig. 5 Correlation between miR-194 level and a FPN1 mRNA or
b ferroportin levels in patients with IIIA and B stages of CRC. Data
presented as relative expression of analyzed genes calculated as
ln 2DDCt or relative amount of protein calculated as ln tumor/
nontumor concentration ratio. Correlation coefficients and statistical
significance were estimated with Pearson’s correlation coefficient
analyses and were r = -0.89, p \ 0.001 for FPN1 mRNA vs. miR-
194, r = -0.66, p = 0.002 for miR-194 versus ferroportin, n = 20.
Dashed lines determine 95 % confidence interval
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HAMP gene mutations in tumor tissues
We performed sequence analyzes of HAMP gene in all
tumor and normal specimens and identified mutations in
the heterozygous state in 4 patients. Two individuals car-
ried HAMP R59G missense mutation, which was previ-
ously described [30]. The effect of this mutation is to
prevent the formation of the 25–amino acid mature peptide
[31], which causes severe hereditary hemochromatosis.
Two other mutations (S4R and Q6E) were novel and
localized in the first exon of HAMP gene encoding C-ter-
minal peptide, which is cut down during the maturation
process of hormone, and probably these alterations do not
influence the maturation process of hepcidin hormone.
Because of small amount of cases with HAMP mutations,
the evaluation of mutation effect on gene expression was
not possible.
Discussion
Proper regulation of iron metabolism is critical for many
important metabolic processes including DNA synthesis,
oxidative cell metabolism, haemoglobin synthesis and cell
respiration. Alternations of iron level disturb the body
homeostasis by forming reactive oxygen species (ROS)
responsible for oxygen stress generation, that leads to many
clinical disorders including carcinogenic events [32, 33]. A
body of evidence suggest, that high dietary iron intake is a
major risk factor for CRC [2, 3]. Diet is thought to be the
aspect of particular interest in the pathogenesis of CRC
since it has been proven to have direct influence on com-
position of intestinal lumen, and through that on the
colonic mucosa [34]. Moreover, it has been shown that
body iron stores were positively associated with the
development of precancerous lesions in the colon, colonic
adenoma or polyps [35]. Posttranscriptional regulation of
iron-related genes in liver, enterocytes and macrophages
has been well characterized, and is associated with the
presence of either IREs [20–22], or sequences homological
for miRNAs in UTRs [23] of several genes involved in iron
metabolism. However, the local role of these genes in
tumor tissues was poorly investigated. We hypothesized,
that there can be alterations in expressing profile of some
genes involved in iron metabolism promoting the accu-
mulation of iron in colonocytes, and this could be an
additional factor contributing to malignant transformation
and tumor progression.
We have shown, that all analyzed iron-related genes
encoding proteins are detectable in both tumor and normal
tissues tested. Fn mRNA and its protein product are highly
expressed in all stages of adenocarcinoma, as well as in
control specimens, which can suggest that normal col-
onocytes and neoplastic colon cells can accumulate high
levels of iron. We investigated the correlations between Fn
and expression levels of several genes (IRP1, IRP2 and
miR-133a), which can play a role in the posttranscriptional
regulation of gene encoding Fn in CRCs. We have shown,
that IRP1 mRNA level is inversely associated with Fn
amount only in more invasive stages of CRC, while miR-
133a is positively correlated with Fn concentration in the
same individuals. It can suggest, that IRP1 could be
involved in regulation mechanism of Fn amount, however
the role of miR-133a in this process remains unclear, since
miRNAs are considered rather as suppressors than activa-
tors of translation process. Perhaps, there is some other
mechanism responsible for regulation of gene encoding Fn,
which could play a role not only in more advanced stages
of this disease.
Since colorectal tissues can collect elevated amount of
iron, we have assessed the mRNA level of iron transporters
in 73 patients with CRC. Our findings confirmed previous
observations, that genes encoding DMT1 and TfR1 are
more often up-regulated in tumor than in normal tissues
Fig. 6 Correlation between ferritin level and a IRP1 mRNA or
b miR-133a levels in patients with IIIA and B stages of CRC. Data
presented as relative expression of analyzed genes calculated as
ln 2DDCt or relative amount of protein calculated as ln tumor/
nontumor concentration ratio. Correlation coefficients and statistical
significance were estimated with Pearson’s correlation coefficient
analyses and were r = -0.97, p \ 0.001 for IRP1 mRNA vs. ferritin,
r = 0.56, p = 0.011 for miR-133a vs. ferritin, n = 20. Dashed lines
determine 95 % confidence interval
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[27], and we attempted to identify the mechanism
responsible for this regulation. Since IRPs can be involved
in posttranscriptional regulation of DMT1 [21], we asses-
sed the correlation between DMT1 and IRPs mRNAs lev-
els. Our experiments revealed, that in early stage of CRC
the level of DMT1 transcript is well associated with IRP1
mRNA level, and in more advanced stages of disease with
IRP2 transcript level. It suggests, that DMT1 mRNA could
be stabilized by both IRPs during the successive progres-
sion of neoplastic process. Simultaneously, IRP2 could be
engaged in the mRNA stabilization of other iron trans-
porter TfR1 in early stage of disease, as it was shown with
the correlation analyzes of mRNA levels. However, in
more advanced stages of CRC, mRNA level of TfR1 is
related to miR-31 level, which suggests, that during the
cancer progression TfR1 gene could be silenced due to
binding of its transcript to homological sequences of miR-
31. We have shown that IRPs mRNA levels are correlated
in various stages of colorectal adenocarcinoma with rela-
tive expression of genes encoding all transporters involved
in iron metabolism. It can suggest that some interactions
among proteins involved in iron metabolism observed in
liver and macrophages can also take place in tumor tissue
of this type of cancer.
In contrast to earlier data, our experiments indicated,
that FPN1 mRNA is significantly elevated in CRC, but the
level of its product ferroportin was significantly reduced. It
was shown that FPN1 expression is regulated at several
levels, including posttranscriptional regulation by the IRE
in 50-UTR bound to IRPs [22], and posttranslational regu-
lation by the action of hepcidin, in response to increased
iron abundance [11]. miR-194 was also considered to play
a role in regulation of FPN1 expression by targeting the 30-
UTR of the transcript, leading to suppression of translation
or rapid degradation of target mRNA, and thus, regulation
of iron metabolism. For the first time we have shown, that
FPN1 mRNA level is significantly and negatively associ-
ated with the level of miR-194, causing the reduction of
transporter amount in tumor tissues of patients with more
advanced stages of CRC. Indeed, assessment of FPN1
concentration in examined tissues confirmed this finding,
which provided novel information on the mechanism of
microRNA-induced iron metabolism regulation. This
observation is also supported by the fact, that in the same
individuals there is a strong inverse correlation between
FPN1 and IRP1 mRNAs levels, which can imply that
during the cancer progression the translation of mRNA into
protein can be less sufficient due to increased amount of
inhibitors of this process. However, the protein level was
not correlated with IRP1 mRNA level, which can suggest
that this inhibitory mechanism is not so effective as that
previously described. Simultaneously, we have not
observed the correlation of FPN1 mRNA level with the
amount of colorectal hepcidin mRNA in patients with more
invasive CRC stages, although expression of HAMP gene
tended to be up-regulated in tumor tissues, as was previ-
ously described in small population of patients [28]. It may
suggest, that this tendency of HAMP overexpression is
related with up-regulation of HFE and HJV genes in
tumors of the same individuals, which is confirmed with
correlation analysis of both transcripts levels. Thus,
reduction of ferroportin amount in tumor tissue, as well as
overexpression of genes responsible for iron intake can
entail the accumulation of iron in neoplastic cells, leading
to increase of Wnt signaling, which has been shown to be
crucial in colorectal carcinogenesis [36].
Since miRNAs play a significant role in many funda-
mental cellular processes such as cell differentiation,
growth, proliferation, and apoptosis, their expression levels
differ between healthy and cancerous tissues. Indeed,
expression profile studies of miRNAs exhibited their pos-
sible tumor suppressor or oncogenic function. To enrich
this findings, we assessed the expression levels of over 300
human miRNAs in 5 % of examined CRC patients. For
further investigation we have chosen genes, which are
homological to 30-UTRs of iron-related genes, according to
the DIANA Database, and reveal altered expression profile.
Among them, miR-31, miR-141, miR-182 and miR-194 are
up-regulated, and miR-133a, miR-145 and miR-149 are
down-regulated. Some of our results are in agreement with
previous observations, where it was shown that miR-133a
and miR-145 were consistently reduced and miR-31 and
miR-182 were regularly overexpressed in colorectal neo-
plasm in comparison to healthy colon mucosa [37–41], but
these alterations are not associated with the stage of CRC.
However, we have also shown, that miR-19a expression
level is not significantly different in adenocarcinoma in
comparison to control specimens, which is in opposite to
previously described data showing overexpression of this
gene in CRC patients [38]. Interestingly, the alterations in
expressing profile of miR-141, miR-149 and mir-194 in
adenocarcinoma specimens have never been documented
yet and are the new findings on this field. In addition, the
expression level of miR-149 is correlated with the depth of
tumor invasion. These alterations are observed even in the
early stage of disease, which can suggest, that miR-31,
miR-133a, miR-141, miR-145, miR-149, miR-182 and
miR-194 could be a potential set of markers for early
detection of colorectal adenocarcinoma, but the level of
this mRNAs in serum has not been investigated yet.
Until recently, the pathologist has been limited in regard to
the classification and prognostication of CRCs to morphologic
and pathologic staging of the tumor. Several statistical analy-
ses from our study supported the conclusion that expression of
genes involved in regulation or mechanism of iron metabolism
can differentiate patients with various stages of colorectal
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adenocarcinoma. We identified a set of genes (DMT1, HAMP,
TfR2, miR-31, miR-149, miR-182, miR-194), which expres-
sion intensities are altered during the progression of disease.
These parameters can explain all analyzed cases assigning
them correctly in dependence of CRC stage. Our findings
suggest, that at the level of colorectal tumor tissue iron
metabolism could be, at least partially, locally regulated,
leading to accumulation of iron and thus promoting cancer
progression. If so, these genes could become potential prog-
nostic indicators for patients with CRC.
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Creative Commons Attribution License which permits any use, dis-
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